Haemonetics buys remaining shares in Arryx
This article was originally published in Clinica
Executive Summary
Blood separation and processing systems developer Haemonetics has agreed to acquire outright Arryx, a privately-held nanotechnology company in which Haemonetics already has a $5m equity stake. The Braintree, Massachusetts-based firm will pay up to $26m in cash for all remaining shares of Arryx.